These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32844866)

  • 1. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
    Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
    J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
    Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
    Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia.
    Kushwaha AC; Mohanbhai SJ; Sardoiwala MN; Sood A; Karmakar S; Roy Choudhury S
    ACS Appl Mater Interfaces; 2020 Jun; 12(23):25633-25644. PubMed ID: 32453568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
    Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
    Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encapsulation of 4-oxo-
    Mrunalini B; Dev A; Kushwaha AC; Sardoiwala MN; Karmakar S
    Nanoscale; 2024 Aug; 16(34):16075-16088. PubMed ID: 39087878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
    Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
    Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
    Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of EZH2-shRNA with mPEG-PEI nanoparticles for the treatment of prostate cancer in vitro.
    Wu Y; Yu J; Liu Y; Yuan L; Yan H; Jing J; Xu G
    Int J Mol Med; 2014 Jun; 33(6):1563-9. PubMed ID: 24714818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
    Li Q; Song W; Wang J
    Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
    Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
    Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
    Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
    Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy.
    Xia Y; Guo M; Xu T; Li Y; Wang C; Lin Z; Zhao M; Zhu B
    Int J Nanomedicine; 2018; 13():1539-1552. PubMed ID: 29588583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
    Nishioka C; Ikezoe T; Yang J; Yokoyama A
    PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silica nanoparticles and polyethyleneimine (PEI)-mediated functionalization: a new method of PEI covalent attachment for siRNA delivery applications.
    Buchman YK; Lellouche E; Zigdon S; Bechor M; Michaeli S; Lellouche JP
    Bioconjug Chem; 2013 Dec; 24(12):2076-87. PubMed ID: 24180511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
    Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
    J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
    Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
    Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.